The University of Chicago Header Logo

Connection

Mark Lingen to Head and Neck Neoplasms

Back to Details
This is a "connection" page, showing publications Mark Lingen has written about Head and Neck Neoplasms.
Mark Lingen
Connection Strength
5.841
Head and Neck Neoplasms
  1. Proceedings of the North American Society of Head and Neck Pathology Companion Meeting, New Orleans, LA, March 12, 2023: Oral Cavity Dysplasia: Why Does Histologic Grading Continue to be Contentious? Head Neck Pathol. 2023 Jun; 17(2):292-298.
    View in: PubMed
    Score: 0.487
  2. A History of Innovations in the Diagnosis and Treatment of Oral and Head and Neck Cancer. J Dent Res. 2019 05; 98(5):489-497.
    View in: PubMed
    Score: 0.368
  3. Assuring dental student head and neck cancer screening competency. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Mar; 111(3):267-8.
    View in: PubMed
    Score: 0.209
  4. Can saliva-based HPV tests establish cancer risk and guide patient management? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Sep; 110(3):273-4.
    View in: PubMed
    Score: 0.202
  5. The changing face of head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Sep; 106(3):315-6.
    View in: PubMed
    Score: 0.176
  6. Tissue microarray - a high-throughput molecular analysis in head and neck cancer. J Oral Pathol Med. 2008 Mar; 37(3):166-76.
    View in: PubMed
    Score: 0.170
  7. Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications. Lab Invest. 2008 Apr; 88(4):342-53.
    View in: PubMed
    Score: 0.169
  8. Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int J Oncol. 2006 May; 28(5):1113-9.
    View in: PubMed
    Score: 0.149
  9. Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2025 May 01; 11(5):492-501.
    View in: PubMed
    Score: 0.139
  10. Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas. Oral Oncol. 2025 Apr; 163:107207.
    View in: PubMed
    Score: 0.138
  11. Update in head and neck oncology. Semin Oncol. 2004 Dec; 31(6):717.
    View in: PubMed
    Score: 0.135
  12. Head and neck cancer: the pursuit of molecular diagnostic markers. Semin Oncol. 2004 Dec; 31(6):718-25.
    View in: PubMed
    Score: 0.135
  13. Switching anti-EGFR antibody re-sensitizes head and neck cancer patient following acquired resistance to cetuximab. Cancer Gene Ther. 2024 Oct; 31(10):1477-1485.
    View in: PubMed
    Score: 0.132
  14. SMYD3 represses tumor-intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neck. Cell Rep. 2023 07 25; 42(7):112823.
    View in: PubMed
    Score: 0.123
  15. Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression. Cancer Res. 2003 Feb 01; 63(3):555-9.
    View in: PubMed
    Score: 0.119
  16. Effect of preradiation dental intervention on incidence of osteoradionecrosis in patients with head and neck cancer: A systematic review and meta-analysis. J Am Dent Assoc. 2022 10; 153(10):931-942.e32.
    View in: PubMed
    Score: 0.116
  17. A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer. Nat Commun. 2022 08 17; 13(1):4829.
    View in: PubMed
    Score: 0.116
  18. Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. Br J Cancer. 2022 11; 127(8):1497-1506.
    View in: PubMed
    Score: 0.115
  19. Retinoic acid modulates the ability of macrophages to participate in the induction of the angiogenic phenotype in head and neck squamous cell carcinoma. Int J Cancer. 2002 Jul 20; 100(3):283-9.
    View in: PubMed
    Score: 0.115
  20. Application of liquid biopsy as multi-functional biomarkers in head and neck cancer. Br J Cancer. 2022 02; 126(3):361-370.
    View in: PubMed
    Score: 0.110
  21. Paracrine angiogenic loop between head-and-neck squamous-cell carcinomas and macrophages. Int J Cancer. 2001 Sep; 93(6):781-5.
    View in: PubMed
    Score: 0.108
  22. Squamous cell carcinoma of the head and neck in nonsmokers: clinical and biologic characteristics and implications for management. Curr Opin Oncol. 2001 May; 13(3):176-82.
    View in: PubMed
    Score: 0.106
  23. New therapeutic strategies for the treatment and prevention of head and neck cancer. Expert Opin Investig Drugs. 2000 Dec; 9(12):2855-72.
    View in: PubMed
    Score: 0.103
  24. The Utility of MDM2 and CDK4 Immunohistochemistry and MDM2 FISH in Craniofacial Osteosarcoma. Head Neck Pathol. 2020 Dec; 14(4):889-898.
    View in: PubMed
    Score: 0.097
  25. Somatic mitochondrial mutation discovery using ultra-deep sequencing of the mitochondrial genome reveals spatial tumor heterogeneity in head and neck squamous cell carcinoma. Cancer Lett. 2020 02 28; 471:49-60.
    View in: PubMed
    Score: 0.096
  26. Angiogenesis in the development of head and neck cancer and its inhibition by chemopreventive agents. Crit Rev Oral Biol Med. 1999; 10(2):153-64.
    View in: PubMed
    Score: 0.090
  27. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. Cancer Res. 1998 Dec 01; 58(23):5551-8.
    View in: PubMed
    Score: 0.089
  28. Histological features and prognostic significance of treatment effect in lymph node metastasis in head and neck squamous cell carcinoma. Histopathology. 2019 Jan; 74(2):321-331.
    View in: PubMed
    Score: 0.089
  29. Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer. J Natl Cancer Inst. 2018 03 01; 110(3).
    View in: PubMed
    Score: 0.085
  30. Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2017 Aug 15; 23(16):4897-4907.
    View in: PubMed
    Score: 0.080
  31. Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. Oncotarget. 2017 Mar 21; 8(12):18726-18734.
    View in: PubMed
    Score: 0.079
  32. WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer. Sci Rep. 2017 01 19; 7:40664.
    View in: PubMed
    Score: 0.079
  33. WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck. Oncotarget. 2016 Jul 05; 7(27):42527-42538.
    View in: PubMed
    Score: 0.076
  34. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):21-9.
    View in: PubMed
    Score: 0.075
  35. Involvement of calprotectin (S100A8/A9) in molecular pathways associated with HNSCC. Oncotarget. 2016 Mar 22; 7(12):14029-47.
    View in: PubMed
    Score: 0.074
  36. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Jun 01; 21(11):2601-12.
    View in: PubMed
    Score: 0.069
  37. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res. 2015 Feb 15; 21(4):870-81.
    View in: PubMed
    Score: 0.068
  38. Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition. Growth Factors. 2014 Dec; 32(6):202-6.
    View in: PubMed
    Score: 0.067
  39. WHSC1 promotes oncogenesis through regulation of NIMA-related kinase-7 in squamous cell carcinoma of the head and neck. Mol Cancer Res. 2015 Feb; 13(2):293-304.
    View in: PubMed
    Score: 0.067
  40. Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma. Oral Oncol. 2015 Jan; 51(1):53-8.
    View in: PubMed
    Score: 0.067
  41. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015 Feb 01; 21(3):632-41.
    View in: PubMed
    Score: 0.066
  42. DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer. PLoS One. 2014; 9(7):e102112.
    View in: PubMed
    Score: 0.066
  43. PTEN deficiency contributes to the development and progression of head and neck cancer. Neoplasia. 2013 May; 15(5):461-71.
    View in: PubMed
    Score: 0.061
  44. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76.
    View in: PubMed
    Score: 0.059
  45. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Apr 15; 18(8):2336-43.
    View in: PubMed
    Score: 0.056
  46. Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin. Head Neck. 2011 Dec; 33(12):1774-82.
    View in: PubMed
    Score: 0.052
  47. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43.
    View in: PubMed
    Score: 0.050
  48. Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. PLoS Comput Biol. 2010 Apr 01; 6(4):e1000730.
    View in: PubMed
    Score: 0.049
  49. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31.
    View in: PubMed
    Score: 0.046
  50. A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle. Cancer Res. 2009 Jan 01; 69(1):65-74.
    View in: PubMed
    Score: 0.045
  51. Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth. Cancer Res. 2007 Oct 15; 67(20):9685-93.
    View in: PubMed
    Score: 0.041
  52. Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase. Cancer Res. 2006 Jun 15; 66(12):6296-303.
    View in: PubMed
    Score: 0.038
  53. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005 Nov 15; 11(22):8105-8.
    View in: PubMed
    Score: 0.036
  54. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol. 2004 May 01; 22(9):1743-52.
    View in: PubMed
    Score: 0.033
  55. Nitric oxide synthase type 3 is increased in squamous hyperplasia, dysplasia, and squamous cell carcinoma of the head and neck. Ann Otol Rhinol Laryngol. 1999 Aug; 108(8):781-7.
    View in: PubMed
    Score: 0.023
  56. Nondestructive, multiplex three-dimensional mapping of immune infiltrates in core needle biopsy. Lab Invest. 2019 09; 99(9):1400-1413.
    View in: PubMed
    Score: 0.022
  57. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 2010 Mar 15; 70(6):2158-64.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.